ROR1 and central nervous system cancer: The results showed that IGFBP5 is a ligand for ROR1, and activates the ROR1/HER2-CREB signaling axis and the transcription of ETV5 and FBXW9. In glioma patients, high IGFBP5 expression alone or in combination with high ETV5 or FBXW9 expression is significantly associated with a poor prognosis.